Proapoptotic compound ARC targets Akt and N-myc in neuroblastoma cells

Oncogene

Volumn 27, Issue 5, 2008, Pages 694-699

  Radhakrishnan, S K ^a,c   Halasi, M ^a   Bhat, U G ^a   Kurmasheva, R T ^b   Houghton, P J ^b   Gartel, A L ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c CALIFORNIA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Akt; ARC; Mcl 1; N myc; Neuroblastoma; Survivin

Indexed keywords

4 AMINO 6 HYDRAZINO 7 BETA DEXTRO RIBOFURANOSYL 7H PYRROLO[2,3 D]PYRIMIDINE 5 CARBOXAMIDE; 5,6 DICHLOROBENZIMIDAZOLE RIBOSIDE; CASPASE 3; PROTEIN KINASE B; PROTEIN MCL 1; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENCY; DRUG TARGETING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MITOCHONDRION; NEUROBLASTOMA CELL; ONCOGENE C MYB; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; MITOCHONDRIA; NEOPLASM PROTEINS; NEUROBLASTOMA; NUCLEOSIDES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MYC; PYRIMIDINES; TUMOR CELLS, CULTURED;

EID: 38549110510     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210692     Document Type: Article

References (31)

1. Brodeur GM. (2003). Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 3: 203-216.
2. Castel V, Canete A. (2004). A comparison of current neuroblastoma chemotherapeutics. Expert Opin Pharmacother 5: 71-80.
3. Castel V, Canete A, Melero C, Acha T, Navajas A, Garcia-Miguel P et al. (2000). Results of the cooperative protocol (N-III-95) for metastatic relapses and refractory neuroblastoma. Med Pediatr Oncol 35: 724-726.
4. Castel V, Canete A, Navarro S, Garcia-Miguel P, Melero C, Acha T et al. (2001). Outcome of high-risk neuroblastoma using a dose intensity approach: improvement in initial but not in long-term results. Med Pediatr Oncol 37: 537-542.
5. Chesler L, Schlieve C, Goldenberg DD, Kenney A, Kim G, McMillan A et al. (2006). Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma. Cancer Res 66: 8139-8146.
6. Donfrancesco A, Jenkner A, Castellano A, Ilari I, Milano GM, De Sio L et al. (2004). Ifosfamide/carboplatin/etoposide (ICE) as front-line, topotecan/cyclophosphamide as second-line and oral temozolomide as third-line treatment for advanced neuroblastoma over one year of age. Acta Paediatr Suppl 93: 6-11.
7. DuBois SG, Kalika Y, Lukens JN, Brodeur GM, Seeger RC, Atkinson JB et al. (1999). Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J Pediatr Hematol Oncol 21: 181-189.
8. Furman WL, Stewart CF, Poquette CA, Pratt CB, Santana VM, Zamboni WC et al. (1999). Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J Clin Oncol 17: 1815-1824.
9. Gojo I, Zhang B, Fenton RG. (2002). The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1. Clin Cancer Res 8: 3527-3538.
10. Goldsby RE, Matthay KK. (2004). Neuroblastoma: evolving therapies for a disease with many faces. Paediatr Drugs 6: 107-122.
11. Houghton PJ, Santana VM. (2002). Clinical trials using irinotecan. J Pediatr Hematol Oncol 24: 84-85.
12. Imaizumi M, Watanabe A, Kikuta A, Takano T, Ito E, Shimizu T et al. (2001). Improved survival of children with advanced neuroblastoma treated by intensified therapy including myeloablative chemotherapy with stem cell transplantation: a retrospective analysis from the Tohoku Neuroblastoma Study Group. Tohoku J Exp Med 195: 73-83.
13. Janicke RU, Sprengart ML, Wati MR, Porter AG. (1998). Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem 273: 9357-9360.
14. Kaneko M, Tsuchida Y, Mugishima H, Ohnuma N, Yamamoto K, Kawa K et al. (2002). Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification. J Pediatr Hematol Oncol 24: 613-621.
15. Kennedy SG, Kandel ES, Cross TK, Hay N. (1999). Akt/Protein kinase B inhibits cell death by preventing the release of cytochrome c from mitochondria. Mol Cell Biol 19: 5800-5810.
16. Ma Y, Cress WD, Haura EB. (2003). Flavopiridol-induced apoptosis is mediated through up-regulation of E2F1 and repression of Mcl-1. Mol Cancer Ther 2: 73-81.
17. Marshall NF, Price DH. (1992). Control of formation of two distinct classes of RNA polymerase II elongation complexes. Mol Cell Biol 12: 2078-2090.
18. Martinou JC, Green DR. (2001). Breaking the mitochondrial barrier. Nat Rev Mol Cell Biol 2: 63-67.
19. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK et al. (1999). Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 341: 1165-1173.
20. Newcomb EW, Tamasdan C, Entzminger Y, Alonso J, Friedlander D, Crisan D et al. (2003). Flavopiridol induces mitochondrial-mediated apoptosis in murine glioma GL261 cells via release of cytochrome c and apoptosis inducing factor. Cell Cycle 2: 243-250.
21. Norris MD, Bordow SB, Marshall GM, Haber PS, Cohn SL, Haber M. (1996). Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma. New Engl J Med 334: 231-238.
22. Peng J, Liu M, Marion J, Zhu Y, Price DH. (1998). RNA polymerase II elongation control. Cold Spring Harb Symp Quant Biol 63: 365-370.
23. Radhakrishnan SK, Bhat UG, Hughes DE, Wang IC, Costa RH, Gartel AL. (2006). Identification of a chemical inhibitor of the oncogenic transcription factor forkhead box m1. Cancer Res 66: 9731-9735.
24. Radhakrishnan SK, Feliciano CS, Najmabadi F, Haegebarth A, Kandel ES, Tyner AL et al. (2004). Constitutive expression of E2F-1 leads to p21-dependent cell cycle arrest in S phase of the cell cycle. Oncogene 23: 4173-4176.
25. Radhakrishnan SK, Gartel AL. (2005). The PPAR-gamma agonist pioglitazone post-transcriptionally induces p21 in PC3 prostate cancer but not in other cell lines. Cell Cycle 4: 582-584.
26. Radhakrishnan SK, Gartel AL. (2006a). CDK9 phosphorylates p53 on serine residues 33, 315 and 392. Cell Cycle 5: 519-521.
27. Radhakrishnan SK, Gartel AL. (2006b). A novel transcriptional inhibitor induces apoptosis in tumor cells and exhibits antiangiogenic activity. Cancer Res 66: 3264-3270.
28. Thompson J, George EO, Poquette CA, Cheshire PJ, Richmond LB, de Graaf SS et al. (1999). Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts. Clin Cancer Res 5: 3617-3631.
29. Thompson J, Guichard SM, Cheshire PJ, Richmond LB, Poquette CA, Ragsdale ST et al. (2001). Development, characterization and therapy of a disseminated model of childhood neuroblastoma in SCID mice. Cancer Chemother Pharmacol 47: 211-221.
30. Valteau-Couanet D, Benhamou E, Vassal G, Stambouli F, Lapierre V, Couanet D et al. (2000). Consolidation with a busulfan-containing regimen followed by stem cell transplantation in infants with poor prognosis stage 4 neuroblastoma. Bone Marrow Transplant 25: 937-942.
31. van Noesel MM, Versteeg R. (2004). Pediatric neuroblastomas: genetic and epigenetic 'danse macabre'. Gene 325: 1-15.